INSM Insmed Incorporated
FY2025 10-K
Insmed Incorporated (INSM) filed its fiscal year 2025 10-K annual report with the SEC on Feb 19, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Development and commercialization of specialty pharmaceuticals focusing on respiratory diseases, including key marketed products ARIKAYCE and BRINSUPRI
- • New product emphasis: BRINSUPRI launch in August 2025 generated $172.7M US sales in 2025, contributing to 66.7% overall revenue growth to $606.4M
Management Discussion & Analysis
- • Revenue not disclosed in provided text, no YoY change available
- • Profitability or margin details not provided in the excerpt
Risk Factors
- • FDA accelerated approval of ARIKAYCE contingent on successful ENCORE confirmatory trial with 425 patients enrolled as of Q4 2024
- • Exposure to inflation affecting suppliers, service providers, and partners across US, Europe, Japan, and global operations
Financial SummaryXBRL
Revenue
$606M
Net Income
-$1.3B
Operating Margin
-205.6%
Net Margin
-210.5%
ROE
-172.8%
Total Assets
$2.3B
EPS (Diluted)
$-6.42
Operating Cash Flow
-$935M
Source: XBRL data from Insmed Incorporated FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Insmed Incorporated
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.